Home » Stocks » CBIO

Catalyst Biosciences, Inc. (CBIO)

Stock Price: $6.23 USD 0.20 (3.32%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
After-hours: $6.31 +0.08 (1.28%) Mar 1, 6:20 PM
Market Cap 194.33M
Revenue (ttm) 18.92M
Net Income (ttm) -50.94M
Shares Out 22.07M
EPS (ttm) -3.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $6.23
Previous Close $6.03
Change ($) 0.20
Change (%) 3.32%
Day's Open 6.30
Day's Range 6.16 - 6.47
Day's Volume 320,305
52-Week Range 3.43 - 8.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced that in connection with its previously announced public ...

GlobeNewsWire - 3 weeks ago

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented positive pre-clinical data from its Marzeptacog alfa (activated) – Marz...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced the closing of an underwritten public offering of 8,700,...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO (the “Company”) today announced the pricing of an underwritten public offering of 8,700,0...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it is offering shares of its common stock in an underwritten publi...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two e-poster presentations at the European Association for Haemophilia...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside ...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) presented a poster today at the 62nd Annual American Society of Hematology (ASH) meetin...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Company's syst...

Zacks Investment Research - 3 months ago

Increased analyst coverage over the last few weeks might led to solid price appreciation for stocks like ODP (ODP), Myers (MYE), Catalyst Biosciences (CBIO), Vicor (VICR) and Bally's (BALY).

Other stocks mentioned: MYE, ODP, VICR
GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare...

Seeking Alpha - 3 months ago

Catalyst Biosciences is targeting the hemophilia space with a strong candidate treating types A and B with inhibitors, and second targeting type B. Current standard of care NovoSeven is admini...

Zacks Investment Research - 3 months ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Catalyst Biosciences (CBIO), UFP Industries (UFPI), VeriSign (VRSN), InMode (INMD) and...

Other stocks mentioned: CSTL, INMD, UFPI, VRSN
GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced a trials in progress poster presentation on Marzeptacog alfa (activated...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended Septemb...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Nassim Usman, Ph.D., president and chief executive officer, and Cl...

GlobeNewsWire - 4 months ago

CB 2782-PEG patent protection extended until at least 2038 CB 2782-PEG patent protection extended until at least 2038

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., senior vice president of translational res...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Nassim Usman, Ph.D., president and chief executive officer and ...

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June...

GlobeNewsWire - 7 months ago

Subcutaneous marzeptacog alfa (activated) (MarzAA) rapidly achieves and maintains therapeutic levels

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today reported that the Compensation Committee of Catalyst’s Board of Directors grant...

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it has been added to the Russell 2000® Index effective at the U....

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two presentations at the upcoming International Society on Thrombosi...

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced the closing of an underwritten public offering of 4,615,384 shares of...

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced the appointment of Mr. Charles Democko as Senior Vice President, Reg...

GlobeNewsWire - 8 months ago

CB 2679d-GT demonstrates robust expression of FIX in multiple preclinical models CB 2679d-GT demonstrates robust expression of FIX in multiple preclinical models

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that it is offering shares of its common stock in an underwritten publ...

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced the appointment of Clinton Musil as its new chief financial officer,...

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced final efficacy and safety data from its Phase 2b trial of DalcA, a n...

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of C...

GlobeNewsWire - 8 months ago

Results support subcutaneous dosing regimen of the Phase 3 Registrational trial Results support subcutaneous dosing regimen of the Phase 3 Registrational trial

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced oral and poster presentations at the upcoming World Foundation of He...

GlobeNewsWire - 9 months ago

MarzAA Phase 3 study first patient enrollment targeted before year end following FDA and EMA regulatory feedback

GlobeNewsWire - 10 months ago

FIX patent including DalcA and CB 2679d-GT, now issued in all major markets FIX patent including DalcA and CB 2679d-GT, now issued in all major markets

Zacks Investment Research - 10 months ago

Top Ranked Momentum Stocks to Buy for April 21st

Other stocks mentioned: CNR, GSV, TRWH
GlobeNewsWire - 10 months ago

Final results to be presented during the second quarter Final results to be presented during the second quarter

Zacks Investment Research - 11 months ago

Catalyst Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the 13th Annual Congress ...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophili...

About CBIO

Catalyst Biosciences, a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Its products include Marzeptacog alfa (activated), a subcutaneously administered... [Read more...]

Industry
Biotechnology
Founded
2002
CEO
Nassim Usman
Employees
34
Stock Exchange
NASDAQ
Ticker Symbol
CBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for CBIO stock is "Buy." The 12-month stock price forecast is 19.20, which is an increase of 208.19% from the latest price.

Price Target
$19.20
(208.19% upside)
Analyst Consensus: Buy